Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1729 - Primary tumor sidedness impacts on prognosis and treatment outcome: results from three randomized studies of panitumumab plus chemotherapy versus chemotherapy or chemotherapy plus bevacizumab in 1<sup>st</sup> and 2<sup>nd</sup> line RAS/BRAF WT mCRC


10 Oct 2016


Poster display


Nele Boeckx


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


N. Boeckx1, A. Toler2, K. Op de Beeck1, G. Kafatos3, V. Deschoolmeester1, C.D. Rolfo4, K. Lowe5, G. Van Camp6, G. Demonty7, M. Peeters1

Author affiliations

  • 1 Center For Oncological Research (core), University of Antwerp, 2610 Wilrijk - Antwerp/BE
  • 2 Center For Observational Research, Amgen, Inc, Thousand Oaks/US
  • 3 Centre For Observational Research (oncology), Amgen Ltd, Uxbridge/GB
  • 4 Phase I - Early Clinical Trials Unit, Antwerp University Hospital, 2650 - Edegem/BE
  • 5 Center For Observational Research, Amgen, Inc, Seattle/US
  • 6 Center For Medical Genetics, University of Antwerp, 2610 Wilrijk - Antwerp/BE
  • 7 Regional Medical Development, Amgen, Inc, Brussels/BE


Abstract 1729


Previous studies have reported that primary side of the tumor has a prognostic impact in mCRC, and may also influence efficacy of biological agents. Previous communications comparing biologicals evaluated patients with KRAS WT or RAS WT. It has been proposed that tumor sidedness is a surrogate for the different biological characteristics of the primary tumors. The aim of this analysis is to compare the association between tumor location and anticancer treatment efficacy in mCRC patients with a RAS/BRAF WT primary tumor.


Data from three Amgen-sponsored clinical trials were analyzed for treatment outcomes in relation to location of the primary tumor. All studies were randomized: a first-line phase 3 (PRIME; NCT00364013), a first-line phase 2 (PEAK; NCT00819780) and a second-line phase 3 (181; NCT00339183) study. In order to have a biomarker refined patient population, only RAS/BRAF WT cases were included. Information on tumor location (left/right colon) was obtained from the free-text surgery descriptions and from the original pathology reports. Primary tumors located in the caecum to transverse colon were coded as right-sided and tumors located from the splenic flexure to rectum were coded as left-sided.


Tumor location ascertainment rate was greater than 80%. Between 80% and 85% of cases are left sided. Results for overall survival (OS), progression-free survival (PFS) and overall response rate (ORR) for each treatment arm in the 3 studies are summarized in table 1. Patients with right-sided tumors did worse for all parameters compared to left sided. Panitumumab provided better outcomes than the comparator on the left side. On the right side, the small number of patients does not allow drawing definitive conclusions, but a lack of efficacy of panitumumab was not confirmed, contradicting previous reports on the impact of tumor sidedness.


The result of these retrospective analyses on a homogenous RAS/BRAF WT subpopulation confirms that primary CRC arising on the right side is associated with poor prognosis regardless of treatment received. Moreover, panitumumab plus chemotherapy provide a benefit over chemotherapy with or without bevacizumab in left-sided tumors. No final conclusions can be drawn on the optimal treatment in patients with right-sided primary tumors.

(CR/PR = complete/partial response; HR = hazard ratio)

n patients (R/L) OS(m) PFS(m) CR + PR(%)
Right left right left right left
PRIME (1st line)
Pmab-FOLFOX 26/156 22.5 (8.1-30.8) 32.5 (27.5-37.6) 8.9 (5.5-11.3) 12.9 (10.0-14.9) 52.0 70.3
FOLFOX 32/148 21.5 (10.8-26.0) 23.6 (18.2-27.7) 7.3 (4.2-11.1) 9.3 (7.7-10.8) 41.2 54.8
HR 0.94 (0.53-1.67) 0.67 (0.56-0.859) 0.71 (0.4-1.27) 0.69 (0.54-0.88)
PEAK (1st line)
Pmab-FOLFOX 13/52 22.5 (8.4-36.9) 43.4 (34.2-63.0) 10.3 (6.1-11.6) 14.6 (11.6-18.1) 69.2 63.5
Beva FOLFOX 13/53 23.3 (6.0-29.0) 32.0 (26.9-48.5) 12.6 (1.8-18.4) 11.5 (9.3-13.0) 46.2 58.5
HR 0.63 (0.26-1.54) 0.77 (0.46-1.28) 0.88 (0.39-2.02) 0.67 (0.44-1.02)
181 (2nd line)
Pmab-FOLFIRI 22/143 11.9 (6.4-16.0) 20.1 (16.6-21.7) 6.8 (3.7-10.3) 8.0 (7.3-9.3) 19 50.7
FOLFIRI 26/144 10.9 (6.7-13.0) 16.9 (15.1-22.2) 3.7 (2.0-5.9) 6.6 (5.3-7.4) 3.8 13.5
HR 0.84 (0.46-1.54) 0.97 (0.76-1.26) 0.62 (0.34-1.13) 0.89 (0.69-1.13)

Clinical trial identification

Not applicable

Legal entity responsible for the study

Amgen Ltd


Amgen Ltd


A. Toler: Amgen contractor. G. Kafatos: Amgen Ltd employee and company stock owner. K. Lowe: Amgen, Inc employee and stock owner. G. Demonty: employee of Amgen. M. Peeters: Research grant, Advisor and speaker Amgen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings